The following list of KPIs serve as baseline measurement for our corporate responsibility activities.

These indicators are measured globally unless otherwise noted and cover all our business units with the exception of joint ventures.


key performance indicators
Research & Development
Top 20 global burdens of illness addressed by our products and pipeline1 53% 55%
GCP/PV audits by regulatory agencies of Merck or clinical trial investigators that led to significant fines, penalties, warning letters or product seizures 0 0
Initiated (new) licenses for new technologies 52 61
Narrative of compounds provided to Product Development Partnerships2 Online Online
Manufacturing & Supply
Product recalls in the United States 0 4
Countries we currently supply with our products 140 140
Local and regional manufacturing partnerships3 130 84
Products available via local and regional manufacturing partnerships NA 34
New product and device registrations4,5 334 437
Local regulatory agency GCP/PV training requests fulfilled that will help strengthen agency capabilities with their GCP/PV compliance oversight role6 Online Online
Products submitted that have achieved WHO prequalification (cumulative) 10 10
Products for which we have access pricing7 19 19
Countries where at least one product has intra-country pricing of public and private sectors8 49 49
Investment into patient- and provider-education programs $93.9M $91.1M
Community Investment
Healthcare workers trained through major programs and partnerships9 51,600 38,166
Investment in partnerships for activities to address underlying barriers to health, such as health system strengthening and capacity building10 $34.7M $23.8M
People reached through our major programs & partnerships9,11 255M 269M
Greenhouse gas emissions
(million metric tons of CO2e)
2.10 1.98
Emissions of volatile organic compounds
(metric tons)
931 807
Water usage (billion gallons) 9.1 9.1
Waste generated (metric tons) 186,500 179,000
Waste recycling rate 54% 52%
EMPLOYEES 2011 2012
Diversity & Inclusion
Executive roles held by women13,14
35% 31%
Women on the Board 17% 17%
Underrepresented ethnic groups on the Board 11% 25%
Underrepresented ethnic groups in the
workforce (U.S.)
29% 24%
Response rate to Merck and MSD Voice Survey 63% 77%
Employees who completed health
assessment (U.S.)
58% 58%
Overall turnover rate15 14% 11%
Lost-Time Injury Rate (LTIR)16 0.30 0.24
Recordable Injury Rate (RIR)16 0.74 0.59
Employees who took release time according to the global policy on employee volunteerism17 11% 15%
Volunteer hours17 213,000 221,000
Employees trained on our Code of Conduct 90% 92%
Substantiated allegations to concerns/issues raised 65% 60%
Reported concerns regarding privacy practices, breaches of privacy, and losses of personal data and devices that were substantiated18 68% 23%
NA: Not available.
1 As defined by the WHO and excluding accidents, premature births and self-inflicted injuries.
2 For information on product development partnerships, visit the “Partnerships” tab here.
3 The number of partnerships decreased in 2012 following the evaluation of the manufacturing capabilities needed to support and sustain our Access goals.
4 Data includes new products and new indications.
5 For information on new registrations by region, click here.
6 For information on local regulatory agency GCP/PV training requests, click here.
7 Differential pricing intended to facilitate access for the at-need population.
8 Countries with an MSD trading equity.
9 “Major” is defined as an investment by Merck’s Office of Corporate Philanthropy and/or The Merck Foundation of more than $300,000 per year and/or an engagement with a national government.
10 Includes investments by Merck’s Office of Corporate Philanthropy and/or The Merck Foundation; also includes funding for nutrition and access to clean water.
11 Includes treatments approved for river blindness and lymphatic filariasis through the Merck MECTIZAN® Donation Program.
12 For more details on our environmental metrics, please download the Excel spreadsheet on our Downloads & Media page.
13 Beginning with 2012, data reported for women are global; previously, these data were limited to the U.S.
14 “Executive” is defined as the Chief Executive Officer and two structural levels below.
15 Overall turnover incorporate all types of turnover, including restructuring.
16 LTIR/RIR: Calculated per OSHA methodology.
17 Figures are based on data collected, reported and estimated worldwide.
18 Privacy concerns include all concerns escalated to the Merck Privacy Office about the company’s privacy practices. Substantiated concerns are those that are determined to be inconsistent with Merck privacy standards or that involve loss, theft or unauthorized access to personal data.

Last Updated August 1, 2013